Results 261 to 270 of about 1,154,039 (314)
Some of the next articles are maybe not open access.
Clinics in Plastic Surgery, 2000
Biologic therapy has evolved as a fourth treatment option for patients with melanoma and other malignancies. Interrelated advances in molecular diagnostics and gene therapy techniques will further accelerate therapeutic advances in this new arena. A variety of biologic therapeutic options available to the patient with high risk melanoma are reviewed.
H, Edington, S, Agarwala, J M, Kirkwood
openaire +2 more sources
Biologic therapy has evolved as a fourth treatment option for patients with melanoma and other malignancies. Interrelated advances in molecular diagnostics and gene therapy techniques will further accelerate therapeutic advances in this new arena. A variety of biologic therapeutic options available to the patient with high risk melanoma are reviewed.
H, Edington, S, Agarwala, J M, Kirkwood
openaire +2 more sources
Biological therapies for psoriasis
Expert Opinion on Biological Therapy, 2013Biological therapies have revolutionized moderate-to-severe psoriasis treatment. Increased understanding of disease pathogenesis has yielded multiple therapeutic targets involving the IL-23/Th17 pathway, while current therapies continue to be monitored for long-term efficacy and safety.This review details current understanding of psoriasis ...
Bobbak, Mansouri +2 more
openaire +2 more sources
Economics of biological therapies
BMJ, 2009Demand for biological drugs is putting pressure on health budgets.
Christopher J, Kelly, Fraz A, Mir
openaire +2 more sources
Biological Therapies in Osteoarthritis
Current Pharmaceutical Design, 2015Given the paucity of effective therapies and the increasing prevalence of osteoarthritis (OA) with ageing and overweight populations, new therapies for this painful, life-impairing condition are desperately needed, for both symptom relief and structural modification.
Claire Y J, Wenham +2 more
openaire +2 more sources
Current Opinion in Pulmonary Medicine, 2010
The use of immunomodulators in asthma has been well established with omalizumab. Evidence is accumulating for other biologic agents. The following article presents an overview of current biologic therapies employed and under investigation in the treatment of asthma.Anti-immunoglobulin E and anti-interleukin-5 are best supported by current evidence ...
David, Gruenberg, William, Busse
openaire +2 more sources
The use of immunomodulators in asthma has been well established with omalizumab. Evidence is accumulating for other biologic agents. The following article presents an overview of current biologic therapies employed and under investigation in the treatment of asthma.Anti-immunoglobulin E and anti-interleukin-5 are best supported by current evidence ...
David, Gruenberg, William, Busse
openaire +2 more sources
Biologic therapies in the vasculitides
Current Opinion in Rheumatology, 2003Monoclonal antibody and recombinant DNA technologies have led to the development of biologic therapies capable of directly targeting selected components of the immune response. With the steady expansion of knowledge regarding the mechanisms of vascular inflammation, the safety and efficacy of biologic agents in the vasculitic diseases are being ...
Carol A, Langford, Michael C, Sneller
openaire +2 more sources
Biological therapies in otology
HNO, 2017Hearing loss is present in millions of people worldwide. Current treatment for patients with severe to profound hearing loss consists of cochlear implantation. Providing the cochlear nerve is intact, patients generally benefit greatly from this intervention, frequently achieving significant improvements in speech comprehension. There are, however, some
A, Roemer +4 more
openaire +2 more sources
Current Opinion in Oncology, 1999
Biologic approaches to lymphoma treatment are now a practical reality rather than a vaguely perceived hope for the future. Interferon alfa seems to have been established as a life-extending therapy for selected patients with follicular lymphoma. Humanized anti-CD20 monoclonal antibody (rituximab) has an authentic 50% response rate in patients with ...
M, Bendandi, D L, Longo
openaire +2 more sources
Biologic approaches to lymphoma treatment are now a practical reality rather than a vaguely perceived hope for the future. Interferon alfa seems to have been established as a life-extending therapy for selected patients with follicular lymphoma. Humanized anti-CD20 monoclonal antibody (rituximab) has an authentic 50% response rate in patients with ...
M, Bendandi, D L, Longo
openaire +2 more sources
Journal of Infusion Nursing, 2012
Biologic therapy includes a diverse group of drugs that act directly on the immune system. Sometimes referred to as "targeted therapy," the biologics include cytokines and monoclonal antibodies. These agents can be genetically engineered versions of naturally occurring substances, or novel compounds used for the treatment of cancer and for nononcology ...
openaire +2 more sources
Biologic therapy includes a diverse group of drugs that act directly on the immune system. Sometimes referred to as "targeted therapy," the biologics include cytokines and monoclonal antibodies. These agents can be genetically engineered versions of naturally occurring substances, or novel compounds used for the treatment of cancer and for nononcology ...
openaire +2 more sources